December 3, 2019 10:50 AM ESTUpdated December 4, 04:40 AM
R&D

Bio­gen boasts PhII win in lu­pus — will any­one turn their head from Alzheimer's to no­tice?

Amber Tong

As the gaze on ad­u­canum­ab in­ten­si­fies in the runup to Bio­gen’s hot­ly-an­tic­i­pat­ed da­ta pre­sen­ta­tion at an Alzheimer’s con­fer­ence this week, the biotech is of­fer­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

A service from the Financial Times